Nathaniel Silver Email & Phone Number

Cambridge, Massachusetts, US

Cambridge, Massachusetts, US

Cambridge, Massachusetts, US

Cambridge, Massachusetts, US

Cambridge, MA, US

• Head of early discovery research. Led modelling efforts, oversaw lead identification efforts, directed in vivo pharmacology studies, and contributed to indication evaluation.
• Led a diverse team of cell biologists, modelers, and pharmacologists responsible for in vitro assay development and screening as well as in vivo efficacy and mechanism of action studies.
• Cultivated relationships with key opinion leaders, developing multiple preclinical research collaborations with academic investigators in the areas of myotonic dystrophy and sarcopenia.
• Created a global network of preclinical research organizations to power in vivo pharmacology studies across multiple program areas including epilepsy, non-alcoholic steatohepatitis, and metabolic disease.
• Partnered with clinical research group to lead scientific explorations and identified key diseases and mechanisms that best leveraged platform technology, ultimately informing strategic direction for research and.
• Worked closely with CSO and CEO to prepare and regularly present research to scientific collaborators, potential partners, and investors as part of both technical due diligence and business development activities in.

Cambridge, MA, US

• Founding scientist and lead developer of a computational platform for the identification of a novel class of oral peptide therapeutics in development for the treatment of non-alcoholic fatty liver disease, muscle.
• Developed a sequence and structural informatics analysis pipeline to guide selection of soluble, aggregation resistant, and bioactive proteins.
• Identified multiple lead candidates currently under clinical evaluation.
• Generated structural models of nutrient receptors and performed docking and virtual screening of small peptide (ant)agonists.
• Drove collection of RNAseq and metabolomic datasets and contributed to mechanism of action determination for a new class of compounds for the treatment of NAFLD/NASH.
• Regularly presented scientific work at internal R&D, scientific advisory, and executive board meetings.

Cambridge, MA, US

• Earned a PhD in computational chemistry studying and developing novel algorithms to improve the computational design and evaluation of small molecules, antibodies, and enzymes.
• Applied structure based, ligand design techniques and worked in collaboration with medicinal chemists at U. Mass Medical School to design novel, inhibitors of drug resistant HIV-1 protease.
• Developed a novel, structure based, enumerative method for the computation of ensemble free energies, enthalpies, and entropies of ligand-receptor binding. Improved virtual ranking and design of small molecule.
• Devised an information theoretic approach to assess coupling of configurational degrees of freedom and understand sources of entropy loss in small molecule inhibitors upon binding. Informed lead optimization and design.
• Created homology models of antibody/Fcγ receptor binding and designed Fc mutants to examine the structural role of glycosylation and electrostatic interactions at the Fc binding interface in IgG/Fcγ receptor engagement.
• Created structural transition state and reaction path models and designed enzyme variants to elucidate the reaction mechanism and improve the activity of a ketol-acid reductoisomerase via reduction of activation free.

Rahway, New Jersey, US

Developed physics-based, maximal affinity models to assess druggability of protein targets in silico.

Phd, Computational Chemistry

Ba, Chemistry, Mathematics